Gothenburg, 2013-08-12 15:12 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) received a trade mark registration for its Company name in the EU by OHIM (Office for Harmonization in the Internal Market).
Immunicums patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body's own immune system to attack harmful substances like tumor cells.
In February 2012, Immunicum initiated its first clinical phase I/II-study with INTUVAX® in metastatic renal cancer, so far showing promising results. In addition, the Swedish Medical Products Agency recently approved the start of Immunicum’s second clinical phase I/II-study in primary liver cancer. The first patients are expected to be treated by the turn of the year.
Immunicum’s patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body's own immune system to attack harmful substances like tumor cells. Immunicum’s shares have been traded since April 22, 2013 at NASDAQ OMX First North under the ticker IMMU.
G&W Fondkommission is chosen as the Company’s Certified Adviser.
Tel: +468-503 000 50. www.gwkapital.se.
For further information please contact:
Jamal El-Mosleh, CEO of Immunicum, 0703-31 90 51,
jamal.el-mosleh@immunicum.com
About Immunicum AB (publ):
Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Because the raw material consists of dendritic cells from healthy donors, Immunicum’s products can be produced in large scale. The vaccines have earlier proven efficacy in animal studies and are now undergoing clinical trials in patients.